We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





New, Highly Accurate, POC Test Measures Level of Neutralizing Antibodies (NAb) to COVID-19, Including Variants

By LabMedica International staff writers
Posted on 22 Dec 2021

A new, highly accurate, point-of-care (POC) test can measure the level of neutralizing antibodies (NAb) to COVID-19, including variants. More...

The test, developed by scientists at the Burnet Institute (Melbourne, Australia) and the Peter Doherty Institute for Infection and Immunity (Melbourne, Australia), provides a readout from a fingerprick of blood in less than 20 minutes. The test is the first of its type globally, and could also be useful to indicate when a vaccine booster may be required. While there are many POC tests that can measure the overall level of antibody to SARS-CoV-2, and use this to estimate neutralizing antibodies, this is the only test to measure neutralizing antibody activity, which correlates with immune protection from serious disease in COVID-19.

The emergence of the Omicron variant, which early studies suggest may be up to 40-times less sensitive to patient NAb than Delta, means that some people will go from having enough NAb to be protected, to not having enough. The test provides a new option for immunity screening to support COVID-19 vaccination and control programs, particularly in time-critical and low- and middle-income settings where laboratory-based testing is difficult or impossible for many to access.

“One of the key elements of the test is that it can work with fingerprick whole blood, which is essential if it is really going to be used at point-of-care,” said study joint supervising author, Associate Professor David Anderson, Burnet Institute Deputy Director and Chief Scientific Officer of the Burnet Diagnostics Initiative.

“We envisage that this test may be part of a set of indications that will help to determine who may need a booster vaccine,” said Dr. Tom Fulford from the Doherty Institute. “This can also be adapted so that it can provide information about whether an individual has protective antibodies against particular variants of concern.”

Related Links:
Burnet Institute 
Doherty Institute 


Platinum Member
Fully Automatic ACLIA Analyzer
MAGLUMI X8
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Automated Clinical Chemistry Analyzer
Envoy 500+
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The researchers Manel Pérez Pons y Carlos Rodriguez Muñoz at the IRBLleida laboratory (Photo courtesy of IRBLleida)

New Blood RNA Markers Help Advance Precision Medicine for Respiratory Patients

Risk stratification in hospitalized respiratory disease, particularly among older adults with COVID-19, remains challenging despite rich clinical datasets. Blood-based non-coding RNA biomarkers are promising,... Read more

Microbiology

view channel
Image: The “broth” used to monitor red blood cell depletion in whole blood spiked with one colony-forming-unit of E. coli bacteria, each incubated at different orbital shaking speeds—left to right: 0 RPM, 65 RPM, 120 RPM and 200 RPM—after four hours of incubation. This culturing raises a bacteria-rich, plasma-like layer of bacteria to the top of the vials, while clusters of stuck blood cells known as a Rouleaux formation sink to the bottom. (Image Credit: Pak Kin Wong)

New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours

Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read more

Pathology

view channel
Image: Researchers evaluated AI models that quantify tumor-infiltrating lymphocytes (TIL) on routine breast tissue slides, where higher TIL levels reflect stronger antitumor response and improved breast cancer outcomes (Image Credit: Shutterstock)

AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells

Breast cancer is the most common cancer in Australian women, with more than 20,000 cases each year. Prognosis can be informed by counting tumor-infiltrating lymphocytes (TILs) on routine pathology slides,... Read more

Industry

view channel
Image: RaDaR ST uses a tumor-informed approach that identifies up to 48 patient-specific variants through whole-exome sequencing and tracks those variants in plasma to detect circulating tumor DNA (ctDNA) at very low variant allele fractions (VAFs) (Photo courtesy of Neogenomics)

Tumor-Informed MRD Assay Gains Medicare Coverage for Immunotherapy Monitoring

NeoGenomics’ RaDaR ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program (MolDX) for monitoring... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.